ONX 0801

Drug Profile

ONX 0801

Alternative Names: BGC 945; BTG-945

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG; The Institute of Cancer Research
  • Developer Onyx Pharmaceuticals; Royal Marsden NHS Foundation Trust; The Institute of Cancer Research
  • Class Antineoplastics; Quinazolines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 06 Jun 2017 Efficacy and safety data from a phase I trial in Solid tumours released by The Institute of Cancer Research
  • 02 Jun 2017 Pharmacokinetics and efficacy data from a phase-I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 11 Mar 2016 Phase-I development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top